The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Nakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T., & Ideura, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12229-5 · Cited by 970
RetractedRachmani, R., Slavachevsky, I., Amit, M., Levi, Z., Kedar, Y., Berla, M., & Ravid, M. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01194.x · Cited by 142
RetractedLevey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · cited 1×
“1 10 These renoprotective effects are attributed to reduction of systemic arterial and glomerular pressures and to inhibition of angiotensin-II-related effects on mesangial cell proliferation and fibrosis.”
BackgroundThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00013 · Cited by 4,615
Anderson, S., Rennke, H. G., & Brenner, B. M. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112528 · Cited by 1,072
McKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J., Probstfield, J., Tsuyuki, R. T., White, M., Rouleau, J., Latini, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.10.1056 · Cited by 692
Understanding the nature of renal disease progression
Remuzzi, G., Ruggenenti, P., & Benigni, A. (1997) · Kidney International · doi:10.1038/ki.1997.2 · Cited by 649
Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Khanna, K., Zuckerman, A., & Stier, C. T. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.451 · Cited by 496
Role of aldosterone in the remnant kidney model in the rat.
Greene, E. L., Kren, S., & Hostetter, T. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118867 · Cited by 479
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466 · cited 2×
“12 20 In a pilot short-term uncontrolled study, we observed that spironolactone effectively reduced proteinuria in non-diabetic CKD patients already treated with ACEIs and/or ARBs.”
BackgroundMyers, B. D., Deen, W. M., & Brenner, B. M. (1975) · Circulation Research · doi:10.1161/01.res.37.1.101 · Cited by 345
Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Zuckerman, A., & Stier, C. T. (1999) · Hypertension · doi:10.1161/01.hyp.33.1.232 · Cited by 310
Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F., & Parving, H.-H. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2106 · Cited by 299
Andersen, S., Tarnow, L., Rossing, P., Hansen, B. V., & Parving, H.-H. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00880.x · Cited by 289
Aldosterone in the development and progression of renal injury
Hollenberg, N. K. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00701.x · Cited by 273
Effect of Activation and Inhibition of the Renin-Angiotensin System on Plasma PAI-1
Brown, N. J., Agirbasli, M. A., Williams, G. H., Litchfield, W. R., & Vaughan, D. E. (1998) · Hypertension · doi:10.1161/01.hyp.32.6.965 · Cited by 269
Chrysostomou, A., & Becker, G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200109203451215 · Cited by 267
Nagase, M., Shibata, S., Yoshida, S., Nagase, T., Gotoda, T., & Fujita, T. (2006) · Hypertension · doi:10.1161/01.hyp.0000222003.28517.99 · Cited by 248
Beneficial impact of spironolactone in diabetic nephropathy
Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Rossing, P., Tarnow, L., & Parving, H.-H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00756.x · Cited by 239
Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion
Sun, Y. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00097-7 · Cited by 230
Tanaka, J., Fujita, H. M., Matsuda, S., Toku, K., Sakanaka, M., & Maeda, N. (1997) · Glia · doi:10.1002/(sici)1098-1136(199705)20:1<23::aid-glia3>3.0.co;2-6 · Cited by 225
Chrysostomou, A., Pedagogos, E., MacGregor, L., & Becker, G. J. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01040905 · Cited by 211
Aldosterone Antagonism Attenuates Obesity-Induced Hypertension and Glomerular Hyperfiltration
de Paula, R. B., da Silva, A. A., & Hall, J. E. (2004) · Hypertension · doi:10.1161/01.hyp.0000105624.68174.00 · Cited by 207 · cited 1×
“In a dog model of obesity-induced hypertension, both BP and GFR decreased after treatment with eplerenone.(33) In all, these studies suggest that antagonists of aldosterone may exert intrarenal hemodynamic changes resulting in an acute decrease in GFR.”
BackgroundNongenomic Vascular Action of Aldosterone in the Glomerular Microcirculation
Arima, S., Kohagura, K., Xu, H.-L., Sugawara, A., Abe, T., Satoh, F., Takeuchi, K., & Ito, S. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000083982.74108.54 · Cited by 202
Vasoactive hormones and renal sclerosis
Egido, J. (1996) · Kidney International · doi:10.1038/ki.1996.82 · Cited by 198
Plasminogen activator inhibitor-1 and the kidney
Eddy, A. A. (2002) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00032.2002 · Cited by 188
Plasma aldosterone concentrations in chronic renal disease
Hené, R. J., Boer, P., Koomans, H. A., & Dorhout Mees, E. J. (1982) · Kidney International · doi:10.1038/ki.1982.14 · Cited by 185
Regression of Existing Glomerulosclerosis by Inhibition of Aldosterone
Aldigier, J. C., Kanjanbuch, T., Ma, L.-J., Brown, N. J., & Fogo, A. B. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004090804 · Cited by 171
Local Angiotensin II and Transforming Growth Factor-β1 in Renal Fibrosis of Rats
Sun, Y., Zhang, J., Zhang, J. Q., & Ramires, F. J. A. (2000) · Hypertension · doi:10.1161/01.hyp.35.5.1078 · Cited by 166
Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications
Epstein, M. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80115-3 · Cited by 158
Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity
Feria, I. G., Pichardo, I., Juárez, P., Ramírez, V., González, M. A., Uribe, N., García-Torres, R., López‐Casillas, F., Gamba, G., & Bobadilla, N. A. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00707.x · Cited by 150
Antagonists of Aldosterone and Proteinuria in Patients With CKD: An Uncontrolled Pilot Study
Bianchi, S., Bigazzi, R., & Campese, V. M. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.03.007 · Cited by 140
Self-citationRoland, B. L., Krozowski, Z. S., & Funder, J. W. (1995) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(95)03559-p · Cited by 135
Kobayashi, N., Hara, K., Tojo, A., Onozato, M. L., Honda, T., Yoshida, K., Mita, S.-I., Nakano, S., Tsubokou, Y., & Matsuoka, H. (2005) · Hypertension · doi:10.1161/01.hyp.0000157408.43807.5a · Cited by 102
Effect of a selective aldosterone receptor antagonist in myocardial infarction
Delyani, J. A., Robinson, E., & Rudolph, A. E. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.2.h647 · Cited by 98
Endothelium-Derived Nitric Oxide Modulates Vascular Action of Aldosterone in Renal Arteriole
Arima, S., Kohagura, K., Xu, H.-L., Sugawara, A., Uruno, A., Satoh, F., Takeuchi, K., & Ito, S. (2003) · Hypertension · doi:10.1161/01.hyp.0000111138.78714.1a · Cited by 94
Rapid Nongenomic Effects of Aldosterone on the Renal Vasculature in Humans
Schmidt, B. M. W., Sammer, U., Fleischmann, I., Schlaich, M. P., Delles, C., & Schmieder, R. E. (2006) · Hypertension · doi:10.1161/01.hyp.0000205224.58715.cc · Cited by 79
Wakisaka, M., Spiro, M. J., & Spiro, R. G. (1994) · Diabetes · doi:10.2337/diab.43.1.95 · Cited by 73
Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease
Shiigai, T., & Shichiri, M. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80003-2 · Cited by 70
Quan, Z. Y., Walser, M., & Hill, G. S. (1992) · Kidney International · doi:10.1038/ki.1992.45 · Cited by 69
Aldosterone: intracellular receptors in human heart
Bonvalet, J. P., Alfaidy, N., Farman, N., & Lombès, M. (1995) · European Heart Journal · doi:10.1093/eurheartj/16.suppl_n.92 · Cited by 60
Ibrahim, H. N., Rosenberg, M. E., & Hostetter, T. H. (1997) · PubMed · Cited by 57
Role of angiotensin II in glomerular injury
Ma, L., & Fogo, A. B. (2001) · Seminars in Nephrology · doi:10.1053/snep.2001.26793 · Cited by 51
Kornel, L., Ramsay, C., Kanamarlapudi, N., Travers, T., & Packer, W. (1982) · Clinical and Experimental Hypertension · doi:10.3109/10641968209061625 · Cited by 43
Nongenomic Renal Effects of Aldosterone: Dependency on NO and Genomic Actions
Chun, T.-Y., & Pratt, J. H. (2006) · Hypertension · doi:10.1161/01.hyp.0000205225.88721.2c · Cited by 17
Cited by
on behalf of The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension, Ogihara, T., Kikuchi, K., Matsuoka, H., Fujita, T., Higaki, J., Horiuchi, M., Imai, Y., Imaizumi, T., Ito, S., et al. (2014) · Hypertension Research · doi:10.1038/hr.2014.68 · Cited by 1,385
Pitt, B., Anker, S. D., Bushinsky, D. A., Kitzman, D. W., Zannad, F., Huang, I.-Z., & on behalf of the PEARL-HF Investigators (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq502 · Cited by 438
The incidence and implications of aldosterone breakthrough
Bomback, A. S., & Klemmer, P. J. (2007) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0575 · Cited by 420
Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan
Vogt, L., Waanders, F., Boomsma, F., de Zeeuw, D., & Navis, G. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007060693 · Cited by 372
Guo, C., Ricchiuti, V., Lian, B. Q., Yao, T. M., Coutinho, P., Romero, J. R., Li, J., Williams, G. H., & Adler, G. K. (2008) · Circulation · doi:10.1161/circulationaha.107.748640 · Cited by 342
Metadata
- Authors
- Bianchi, S., Bigazzi, R., & Campese, V. M.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2006-12
- Volume
- 70
- Issue
- 12
- Pages
- 2116-2123
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2020811647
- Cited by
- 338
- References
- 48
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.